KRAS and familial pancreatic carcinoma: In humans, nearly 90% of pancreatic cancer patients show mutations in KRAS (cBioportal) (Cerami et al., 2012), and our autochthonous models were based on mutations in KRAS or in upstream signaling receptors (EGFR).